WHO Issues Warning Over Acute Scarcity of Weight-Loss Medications

Less than a tenth of patients eligible to benefit from weight-loss injections such as Wegovy are able to get them, states the World Health Organization as it publishes its inaugural advice on the therapies.

Given in excess of 1,000,000,000 individuals worldwide now classified as obese, it is urging more widespread and fairer access to this class of drugs.

Per projections, in excess of 2,000,000,000 could be obese by 2030 if no action is taken.

"Our latest guidelines acknowledges that excess weight is a long-term condition that can be treated with comprehensive and lifelong treatment," stated the agency's head Tedros Adhanom Ghebreyesus.

Significant expense, limited production capacity, and logistical bottlenecks are key barriers to universal availability to the jabs that can aid individuals in losing significant body mass, notes the agency.

Skinny Jab Shortage

Despite the present best projected case, the production of such drugs could only cover about 100 million people – under 10% of those who need them, per the health organization.

The advice encourages countries and companies to expand access, by approaches like voluntary licensing.

Exclusive production rights on semaglutide – the main ingredient of the drug Wegovy – is scheduled to end in a number of nations in 2026.

The Way Obesity Jabs Work

The injections replicate a biological compound to slow digestion, reduce hunger and enhance feelings of fullness so individuals eat less.

Individuals commonly see weight reduction in the initial weeks of commencing the regular doses.

Research indicates users may regain a significant portion after a year of discontinuing the drug, as their usual hunger come back.

Being carrying excess weight increases your likelihood for developing medical conditions, like type 2 diabetes, heart disease, brain attack, and specific malignancies.

Obesity impacts individuals in countries worldwide and was responsible for over three and a half million fatalities worldwide in 2024, per the health agency.